Cargando…
Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
Survival of activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL) is driven by chronic B cell receptor (BCR) signaling that activates the canonical NF-κB pathway. Inhibition of BTK by Ibrutinib has been shown to kill ABC DLBCL cells that carry activating mutations in the BCR adapto...
Autores principales: | Nagel, Daniel, Bognar, Miriam, Eitelhuber, Andrea C., Kutzner, Kerstin, Vincendeau, Michelle, Krappmann, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747221/ https://www.ncbi.nlm.nih.gov/pubmed/26540570 |
Ejemplares similares
-
AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-κB signaling upon T cell activation
por: Schimmack, Gisela, et al.
Publicado: (2014) -
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023) -
Attacking MALT1 for ABC-DLBCL therapy
por: Krappmann, Daniel
Publicado: (2012) -
Combining precision oncology and immunotherapy by targeting the MALT1 protease
por: Mempel, Thorsten R, et al.
Publicado: (2022) -
Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells
por: Meininger, Isabel, et al.
Publicado: (2016)